Research programme: cell therapies - Rexgeneron
Latest Information Update: 09 Aug 2016
At a glance
- Originator Rexgenero
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cardiovascular disorders; Neurological disorders
Most Recent Events
- 09 Aug 2016 Early research in Neurological disorders in United Kingdom (Parenteral)
- 09 Aug 2016 Early research in Cardiovascular disorders in United Kingdom (Parenteral)